Physician profile

Scott Fertels

Cardiovascular Disease · Haddon Heights, NJ

NPI 1871544718

$7,260.26

in general payments reported to CMS, 2019-2025

36 companies · $1,206 in 2025

The $1,206 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

See the full distribution for Cardiovascular Disease

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,395.59

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $1,207.32 2019-2025
Amgen INC. $673.89 2019-2025 Repatha, Repatha
Impulse Dynamics (USA) INC. $665.76 2021-2025 Optimizer, Optimizer
Pfizer INC. $598.28 2019-2025
Abbott Laboratories $452.40 2019-2025 Aveir, Hi-Torque Advance, Cardiomems
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $434.15 2019-2025 Lifevest
Amarin Pharma, INC. $379.42 2019-2021
Janssen Pharmaceuticals, INC $322.20 2019-2024 Xarelto
Merck Sharp & Dohme LLC $308.13 2021-2025 Verquvo
Boston Scientific Corporation $296.89 2019-2025 Watchman Flx, Bodyguardian
Astrazeneca Pharmaceuticals LP $282.11 2019-2025 Farxiga
Medtronic Vascular, INC. $202.20 2019
Sanofi-Aventis U.S. LLC $170.79 2019-2022
Esperion Therapeutics, INC. $161.31 2020-2025 Nexletol
E.R. Squibb & Sons, L.L.C. $129.62 2019-2025 Camzyos, Eliquis
Show all 36 companies
CompanyGeneral paymentsYearsTop products
Medtronic, INC. $117.35 2024 Pipeline
W. L. Gore & Associates, INC. $114.58 2020-2022
Boehringer Ingelheim Pharmaceuticals, INC. $100.33 2019-2025 Jardiance
Inspire Medical Systems, INC. $82.84 2024-2025 Inspire
Scpharmaceuticals INC. $77.59 2024-2025
Regeneron Healthcare Solutions, INC. $69.89 2019-2023 Evkeeza
Cvrx, INC. $66.47 2024 Barostim Neo System
Bayer Healthcare Pharmaceuticals INC. $58.78 2021-2024
Kiniksa Pharmaceuticals International, Plc $49.55 2024 Arcalyst
Philips North America LLC $35.18 2023-2024 (5044) Mcot
Genzyme Corporation $34.70 2021-2023
Novo Nordisk INC $26.96 2021-2025 Wegovy
Lundbeck LLC $24.68 2019-2020
Chiesi USA, INC. $18.82 2021
Regeneron Pharmaceuticals, INC. $16.80 2019
Daiichi Sankyo INC. $15.33 2023 Injectafer
Cmp Pharma, INC. $15.31 2022
Kowa Pharmaceuticals America, INC. $13.58 2019
Glaxosmithkline, LLC. $13.46 2025 Shingrix, Arexvy
Astellas Pharma US INC $11.81 2019
Otsuka America Pharmaceutical, INC. $11.78 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Scott Fertels

$7,260.26

in general payments reported 2019-2025

Years
2019-2025
Top company
Novartis Pharmaceuticals Corporation
Context
The $1,206 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/129610/scott-fertels

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.